A researcher and entrepreneur based in St. Louis, Missouri, Thomas Brutnell holds a Ph.D. in biology from Yale University and several decades of research in plant genomics and genetics. Thomas Brutnell is the founder and president of Viridis Genomics Consulting and the vice president of Gateway Biotechnology.
In October 2019, Gateway Biotechnology secured a United States patent to develop a compound derived from a Chinese medicinal plant to treat noise-induced hearing loss (NIHL). In pre-clinical trials, tetrandrine (TET) was efficacious in preventing and treating NIHL. According to preliminary research, TET could protect against as much as 83 percent of noise-induced damage, with the protective effects lasting as far as 48 weeks after noise exposure.
To date, the FDA has not approved any therapeutics for the treatment of NIHL. However, with the new patent, Gateway Biotechnology can rapidly begin clinical studies in individuals at risk of NIHL. For more information about Gateway’s innovative hearing loss research, visit www.gatewaybiotechnology.com.
In October 2019, Gateway Biotechnology secured a United States patent to develop a compound derived from a Chinese medicinal plant to treat noise-induced hearing loss (NIHL). In pre-clinical trials, tetrandrine (TET) was efficacious in preventing and treating NIHL. According to preliminary research, TET could protect against as much as 83 percent of noise-induced damage, with the protective effects lasting as far as 48 weeks after noise exposure.
To date, the FDA has not approved any therapeutics for the treatment of NIHL. However, with the new patent, Gateway Biotechnology can rapidly begin clinical studies in individuals at risk of NIHL. For more information about Gateway’s innovative hearing loss research, visit www.gatewaybiotechnology.com.
